Findings

What do systematic reviews say?

4,808 questions · 8,953 findings · 827 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1,891 · 21.1%GRADE not reported 380 · 4.2%Very low 2,100 · 23.5%Low 2,449 · 27.4%Moderate 1,684 · 18.8%High 449 · 5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Sclerotherapy vs placebo

Time to resolution · people with telangiectasias and reticular veins

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sclerotherapy vs placebo

Quality of life · people with telangiectasias and reticular veins

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Psychotherapy vs usual care

BPD symptom severity Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · patients with borderline personality disorder

1 finding from 1 review

Psychological therapies for people with borderline personality disorder 2020 · Cochrane Headline outcomes only
no estimate extracted
22 studies · 1244 participants
Moderate

Psychotherapy vs no treatment or waiting list

Suicide‐related outcomes Timing of outcome assessment: end of treatment (6 to 12 weeks treatment duration) · patients with borderline personality disorder

1 finding from 1 review

Psychological therapies for people with borderline personality disorder 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 108 participants
Very low

Psychotherapy vs no treatment or waiting list

Psychosocial functioning Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · patients with borderline personality disorder

1 finding from 1 review

Psychological therapies for people with borderline personality disorder 2020 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 219 participants
Low

Psychotherapy vs no treatment or waiting list

Depressive symptoms · patients with borderline personality disorder

1 finding from 1 review

Psychological therapies for people with borderline personality disorder 2020 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 239 participants
Low

Psychotherapy vs no treatment or waiting list

Attrition Timing of outcome assessment: end of treatment · patients with borderline personality disorder

It is very uncertain whether psychotherapy changes attrition Timing of outcome assessment: end of treatment compared with waiting list or no treatment (very low certainty).

1 finding from 1 review

Psychological therapies for people with borderline personality disorder 2020 · Cochrane Headline outcomes only
RR 0.55 [0.2, 1.5]
3 studies · 144 participants
Very low

Psychotherapy vs no treatment or waiting list

Adverse effects (not measured · patients with borderline personality disorder

The review found no eligible studies for this question.

1 finding from 1 review

Psychological therapies for people with borderline personality disorder 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Psychotherapy vs usual care

Self harm ‐ frequency of self harm · patients with borderline personality disorder

1 finding from 1 review

Psychological therapies for people with borderline personality disorder 2020 · Cochrane Headline outcomes only
no estimate extracted
13 studies · 616 participants
Low

Psychotherapy vs usual care

Suicide‐related outcomes Timing of outcome assessment: end of treatment (6 to 12 weeks treatment duration) · patients with borderline personality disorder

1 finding from 1 review

Psychological therapies for people with borderline personality disorder 2020 · Cochrane Headline outcomes only
no estimate extracted
13 studies · 666 participants
Low

Psychotherapy vs usual care

Psychosocial functioning Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · patients with borderline personality disorder

1 finding from 1 review

Psychological therapies for people with borderline personality disorder 2020 · Cochrane Headline outcomes only
no estimate extracted
22 studies · 1314 participants
Low

Psychotherapy vs usual care

Depressive symptoms · patients with borderline personality disorder

1 finding from 1 review

Psychological therapies for people with borderline personality disorder 2020 · Cochrane Headline outcomes only
no estimate extracted
22 studies · 1568 participants
Very low

Psychotherapy vs usual care

Attrition Timing of outcome assessment: end of treatment · patients with borderline personality disorder

Psychotherapy showed no clear difference in attrition Timing of outcome assessment: end of treatment compared with treatment‐as‐usual (low certainty).

1 finding from 1 review

Psychological therapies for people with borderline personality disorder 2020 · Cochrane Headline outcomes only
RR 1 [0.83, 1.2]
32 studies · 2225 participants
Low

Psychotherapy vs usual care

Adverse effects Timing of outcome assessment: end of treatment · patients with borderline personality disorder

Psychotherapy showed no clear difference in adverse effects Timing of outcome assessment: end of treatment compared with treatment‐as‐usual (low certainty).

1 finding from 1 review

Psychological therapies for people with borderline personality disorder 2020 · Cochrane Headline outcomes only
RR 0.92 [0.45, 1.88]
2 studies · 381 participants
Low

Psychotherapy vs no treatment or waiting list

BPD symptom severity Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · patients with borderline personality disorder

1 finding from 1 review

Psychological therapies for people with borderline personality disorder 2020 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 161 participants
Low

Psychotherapy vs no treatment or waiting list

Deliberate self‐harm · patients with borderline personality disorder

1 finding from 1 review

Psychological therapies for people with borderline personality disorder 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 128 participants
Low

Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy

Overall survival (OS) · platinum‐sensitive recurrent EOC

Summary of findings 1: PLD with chemotherapy showed no clear difference in overall survival (OS) compared with alternative combination chemotherapy (moderate certainty).

1 finding from 1 review

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
HR 0.93 [0.83, 1.04]
5 studies · 2006 participants
Moderate

Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy

Progression‐free survival · platinum‐sensitive recurrent EOC

Summary of findings 1: PLD with chemotherapy probably leads to lower progression‐free survival (PFS) compared with alternative combination chemotherapy (moderate certainty).

1 finding from 1 review

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
HR 0.81 [0.74, 0.89]
5 studies · 2006 participants
Moderate

Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy

QoL · platinum‐sensitive recurrent EOC

1 finding from 1 review

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 608 participants
Low

Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy

Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC

Summary of findings 1: PLD with chemotherapy showed no clear difference in overall severe adverse events (grade ≥ 3) compared with alternative combination chemotherapy (moderate certainty).

1 finding from 1 review

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
RR 1.11 [0.95, 1.3]
2 studies · 834 participants
Moderate